Revenue grew 16% year-over-year to DKK 8.3 million in 2025, led by Pharma and Aquaculture. Liquidity was strengthened by a DKK 15.8 million capital raise, supporting growth plans. 2026 revenue is guided at DKK 10–13 million, with recurring sales expected to accelerate.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.